1. Home
  2. FNKO vs OMER Comparison

FNKO vs OMER Comparison

Compare FNKO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FNKO
  • OMER
  • Stock Information
  • Founded
  • FNKO 2017
  • OMER 1994
  • Country
  • FNKO United States
  • OMER United States
  • Employees
  • FNKO 1280
  • OMER N/A
  • Industry
  • FNKO Recreational Games/Products/Toys
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • FNKO Consumer Discretionary
  • OMER Health Care
  • Exchange
  • FNKO Nasdaq
  • OMER Nasdaq
  • Market Cap
  • FNKO 667.2M
  • OMER 667.0M
  • IPO Year
  • FNKO 2017
  • OMER 2009
  • Fundamental
  • Price
  • FNKO $12.32
  • OMER $10.11
  • Analyst Decision
  • FNKO Strong Buy
  • OMER Buy
  • Analyst Count
  • FNKO 3
  • OMER 4
  • Target Price
  • FNKO $13.83
  • OMER $22.50
  • AVG Volume (30 Days)
  • FNKO 996.0K
  • OMER 1.2M
  • Earning Date
  • FNKO 11-07-2024
  • OMER 11-13-2024
  • Dividend Yield
  • FNKO N/A
  • OMER N/A
  • EPS Growth
  • FNKO N/A
  • OMER N/A
  • EPS
  • FNKO N/A
  • OMER N/A
  • Revenue
  • FNKO $1,047,357,000.00
  • OMER N/A
  • Revenue This Year
  • FNKO N/A
  • OMER N/A
  • Revenue Next Year
  • FNKO $7.90
  • OMER N/A
  • P/E Ratio
  • FNKO N/A
  • OMER N/A
  • Revenue Growth
  • FNKO N/A
  • OMER N/A
  • 52 Week Low
  • FNKO $5.36
  • OMER $2.61
  • 52 Week High
  • FNKO $12.86
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • FNKO 59.89
  • OMER 57.55
  • Support Level
  • FNKO $11.26
  • OMER $7.20
  • Resistance Level
  • FNKO $12.86
  • OMER $13.60
  • Average True Range (ATR)
  • FNKO 0.61
  • OMER 1.35
  • MACD
  • FNKO 0.07
  • OMER -0.21
  • Stochastic Oscillator
  • FNKO 70.97
  • OMER 45.47

About FNKO Funko Inc.

Funko Inc is an us-based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: